Šalis: Kanada
kalba: anglų
Šaltinis: Health Canada
ROSUVASTATIN (ROSUVASTATIN CALCIUM)
NORA PHARMA INC
C10AA07
ROSUVASTATIN
5MG
TABLET
ROSUVASTATIN (ROSUVASTATIN CALCIUM) 5MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0148963004; AHFS:
APPROVED
2023-03-30
PRODUCT MONOGRAPH Pr NRA-ROSUVASTATIN TABLETS ROSUVASTATIN TABLETS 5 MG, 10 MG, 20 MG AND 40 MG ROSUVASTATIN (AS ROSUVASTATIN CALCIUM) Manufacturer Standard LIPID METABOLISM REGULATOR Nora Pharma Inc. 1565, boul. Lionel-Boulet Varennes, Quebec J3X 1P7 Control # 272335 Date of Preparation: MAR 28, 2023 Page 2 of 46 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................................................................... 3 SUMMARY PRODUCT INFORMATION .................................................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................................................... 3 CONTRAINDICATIONS ............................................................................................................................... 4 WARNINGS AND PRECAUTIONS .............................................................................................................. 5 ADVERSE REACTIONS .............................................................................................................................. 10 DRUG INTERACTIONS .............................................................................................................................. 15 DOSAGE AND ADMINISTRATION .......................................................................................................... 21 OVERDOSAGE ............................................................................................................................................. 24 ACTION AND CLINICAL PHARMACOLOGY ......................................................................................... 24 STORAGE AND STABILITY ...................................................................................................................... 26 DOSAGE FORMS, COMPOSITION AND PACKAGING .......................................................................... 26 PART II: SCIENTIFIC INFORMATION ........................ Perskaitykite visą dokumentą